secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001023024-24-000083
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q2 record revenues $138M (+18% YoY); raises FY guidance
------------------------------------------------------------------

- Record Q2 net revenues $138.0M (+18.4% YoY); Rare Disease Cortrophin Gel $49.2M (+102.4% YoY).
- GAAP net loss $(2.7)M ($(0.14)/share); adjusted non-GAAP diluted EPS $1.02; adjusted EBITDA $33.2M.
- Raised FY 2024 guidance: rev $540M-$560M, adj. EBITDA $140M-$150M, adj. EPS $4.38-$4.82.
- On track to acquire Alimera Sciences (~$5.50/sh cash + CVR) in Q3 2024, adding ILUVIEN and YUTIQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000083/0001023024-24-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000083/ani-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer